Do analysts prefer MBRX or AGFY?

Moleculin Biotech currently has a consensus price target of $3.00, indicating a potential upside of 344.12%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MBRX or AGFY more profitable?

Moleculin Biotech has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Moleculin Biotech's return on equity of -143.51% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Agrify -424.11% -185.90% -72.67%

Which has better valuation & earnings, MBRX or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is MBRX or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Grace Therapeutics N/A -36.11% -34.39%

Does the media favor MBRX or GRCE?

In the previous week, Moleculin Biotech had 7 more articles in the media than Grace Therapeutics. MarketBeat recorded 8 mentions for Moleculin Biotech and 1 mentions for Grace Therapeutics. Moleculin Biotech's average media sentiment score of 0.11 beat Grace Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MBRX or VERU more profitable?

Veru's return on equity of -47.58% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Veru N/A -47.58% -35.83%

Does the media prefer MBRX or VERU?

In the previous week, Moleculin Biotech had 6 more articles in the media than Veru. MarketBeat recorded 8 mentions for Moleculin Biotech and 2 mentions for Veru. Veru's average media sentiment score of 0.34 beat Moleculin Biotech's score of 0.11 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, MBRX or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is MBRX or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Cassava Sciences N/A -58.78% -36.74%

Is IXHL or MBRX more profitable?

Incannex Healthcare's return on equity of -81.01% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Moleculin Biotech N/A -143.51% -24.53%

Moleculin Biotech (MBRX) Competitors

$0.68 -0.02 (-2.67%)

As of 04:00 PM Eastern

Compare

MBRX vs. AGFY, GRCE, VERU, FLNA, and IXHL

Should you buy Moleculin Biotech stock or one of its competitors? Moleculin Biotech's main competitors and comparable companies include Agrify (AGFY), Grace Therapeutics (GRCE), Veru (VERU), Cassava Sciences (FLNA), and Incannex Healthcare (IXHL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Moleculin Biotech compare to Agrify?

Moleculin Biotech (NASDAQ:MBRX) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Moleculin Biotech has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Moleculin Biotech's return on equity of -143.51% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Agrify	-424.11%	-185.90%	-72.67%

Moleculin Biotech has higher earnings, but lower revenue than Agrify. Agrify is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Agrify	$12.26M	3.92	-$41.75M	-$22.65	N/A

Moleculin Biotech has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, meaning that its stock price is 896% more volatile than the broader market.

Moleculin Biotech currently has a consensus price target of $3.00, indicating a potential upside of 344.12%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Moleculin Biotech had 8 more articles in the media than Agrify. MarketBeat recorded 8 mentions for Moleculin Biotech and 0 mentions for Agrify. Moleculin Biotech's average media sentiment score of 0.11 beat Agrify's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
Agrify	Neutral

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 6.0% of Agrify shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by insiders. Comparatively, 2.2% of Agrify shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Moleculin Biotech beats Agrify on 13 of the 15 factors compared between the two stocks.

How does Moleculin Biotech compare to Grace Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Moleculin Biotech presently has a consensus price target of $3.00, suggesting a potential upside of 344.12%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 180.37%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -36.11% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Grace Therapeutics	N/A	-36.11%	-34.39%

Moleculin Biotech has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Moleculin Biotech had 7 more articles in the media than Grace Therapeutics. MarketBeat recorded 8 mentions for Moleculin Biotech and 1 mentions for Grace Therapeutics. Moleculin Biotech's average media sentiment score of 0.11 beat Grace Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Moleculin Biotech beats Grace Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to Veru?

Moleculin Biotech (NASDAQ:MBRX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Veru has higher revenue and earnings than Moleculin Biotech. Veru is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Veru	$16.89M	2.68	-$22.73M	-$0.69	N/A

Moleculin Biotech presently has a consensus price target of $3.00, indicating a potential upside of 344.12%. Veru has a consensus price target of $24.50, indicating a potential upside of 824.53%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veru's return on equity of -47.58% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Veru	N/A	-47.58%	-35.83%

In the previous week, Moleculin Biotech had 6 more articles in the media than Veru. MarketBeat recorded 8 mentions for Moleculin Biotech and 2 mentions for Veru. Veru's average media sentiment score of 0.34 beat Moleculin Biotech's score of 0.11 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, suggesting that its stock price is 217% less volatile than the broader market.

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Veru beats Moleculin Biotech on 7 of the 12 factors compared between the two stocks.

How does Moleculin Biotech compare to Cassava Sciences?

Moleculin Biotech (NASDAQ:MBRX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Moleculin Biotech presently has a consensus price target of $3.00, suggesting a potential upside of 344.12%. Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 503.65%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Moleculin Biotech had 8 more articles in the media than Cassava Sciences. MarketBeat recorded 8 mentions for Moleculin Biotech and 0 mentions for Cassava Sciences. Moleculin Biotech's average media sentiment score of 0.11 beat Cassava Sciences' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
Cassava Sciences	Neutral

Cassava Sciences' return on equity of -58.78% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Cassava Sciences	N/A	-58.78%	-36.74%

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cassava Sciences is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Moleculin Biotech has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

Summary

Moleculin Biotech beats Cassava Sciences on 9 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 453.85%. Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 344.12%. Given Incannex Healthcare's higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Incannex Healthcare's return on equity of -81.01% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Moleculin Biotech	N/A	-143.51%	-24.53%

Incannex Healthcare has a beta of 6.97, meaning that its share price is 597% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Moleculin Biotech has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	432.25	-$46.88M	-$1.55	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, Moleculin Biotech had 8 more articles in the media than Incannex Healthcare. MarketBeat recorded 8 mentions for Moleculin Biotech and 0 mentions for Incannex Healthcare. Moleculin Biotech's average media sentiment score of 0.11 beat Incannex Healthcare's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Moleculin Biotech	Neutral

Summary

Moleculin Biotech beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.52M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.09	787.27	273.28	25.38
Price / Sales	N/A	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	1.14	12.33	12.89	6.14
Net Income	-$33.56M	$2.82B	$3.47B	$349.01M
7 Day Performance	-1.92%	1.97%	-0.33%	-1.47%
1 Month Performance	58.94%	4.87%	6.51%	2.47%
1 Year Performance	-92.80%	9.15%	25.19%	15.84%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	3.3365 of 5 stars	$0.68 -2.7%	$3.00 +344.1%	-92.7%	$13.52M	N/A	N/A	20	News Coverage Analyst Revision
AGFY Agrify	N/A	$23.50 +2.3%	N/A	-51.2%	$47.06M	$12.26M	N/A	140	Gap Up
GRCE Grace Therapeutics	1.4563 of 5 stars	$2.15 -2.3%	$6.00 +179.1%	-28.4%	$46.28M	N/A	N/A	N/A	News Coverage Positive News
VERU Veru	2.7097 of 5 stars	$2.80 +3.3%	$24.50 +775.0%	-16.2%	$46.21M	$16.89M	N/A	230	News Coverage
FLNA Cassava Sciences	1.3788 of 5 stars	$0.92 -2.6%	$5.00 +440.9%	-62.2%	$45.83M	N/A	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. AGFY, GRCE, VERU, FLNA, and IXHL

How does Moleculin Biotech compare to Agrify?

Summary

How does Moleculin Biotech compare to Grace Therapeutics?

Summary

How does Moleculin Biotech compare to Veru?

Summary

How does Moleculin Biotech compare to Cassava Sciences?

Summary

How does Moleculin Biotech compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. AGFY, GRCE, VERU, FLNA, and IXHL

How does Moleculin Biotech compare to Agrify?

Is MBRX or AGFY more profitable?

Which has stronger earnings and valuation, MBRX or AGFY?

Which has more risk & volatility, MBRX or AGFY?

Do analysts prefer MBRX or AGFY?

Does the media favor MBRX or AGFY?

Do insiders & institutionals hold more shares of MBRX or AGFY?

Summary

How does Moleculin Biotech compare to Grace Therapeutics?

Which has better valuation & earnings, MBRX or GRCE?

Do analysts recommend MBRX or GRCE?

Is MBRX or GRCE more profitable?

Which has more volatility and risk, MBRX or GRCE?

Do insiders and institutionals hold more shares of MBRX or GRCE?

Does the media favor MBRX or GRCE?

Summary

How does Moleculin Biotech compare to Veru?

Which has higher valuation and earnings, MBRX or VERU?

Do analysts prefer MBRX or VERU?

Is MBRX or VERU more profitable?

Does the media prefer MBRX or VERU?

Which has more risk and volatility, MBRX or VERU?

Do institutionals and insiders have more ownership in MBRX or VERU?

Summary

How does Moleculin Biotech compare to Cassava Sciences?

Do analysts prefer MBRX or FLNA?

Does the media refer more to MBRX or FLNA?

Is MBRX or FLNA more profitable?

Do institutionals & insiders hold more shares of MBRX or FLNA?

Which has stronger valuation & earnings, MBRX or FLNA?

Which has more volatility and risk, MBRX or FLNA?

Summary

How does Moleculin Biotech compare to Incannex Healthcare?

Do analysts rate IXHL or MBRX?

Do institutionals and insiders have more ownership in IXHL or MBRX?

Is IXHL or MBRX more profitable?

Which has more volatility & risk, IXHL or MBRX?

Which has better earnings and valuation, IXHL or MBRX?

Does the media prefer IXHL or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools